Erythropoietin recombinant human
Sold as Eprex
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Janssen Pharmaceutica (Pty) Ltd1 of 2 cancelled | Eprex | 10 000, 4000 | W0220, W0221 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Eprex 4000 * EACH 1 ml CONTAINS ERYTHROPOIETIN RECOMBINANT HUMAN 4 000 units | 4000 | W0220W/30.4/220 | Cancelled | Not determined | None |
| Eprex 10 000 * EACH 1 ml CONTAINS ERYTHROPOIETIN RECOMBINANT HUMAN 10 000 units | 10 000 | W0221W/30.4/221 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.